Anuh Pharma credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
0.00.010.5
−53.2−53.2−63.1
0.00×0.00×0.03×
−0.15×−0.15×−0.19×
0.00×0.00×0.17×
−0.82×−0.86×−1.04×
106.58×106.58×84.24×
0.0%0.0%3.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ANUHPHR₹79.74

Anuh Pharma Limited

· Pharma & Health
₹ CrorePeersAHCLWANBURYZIMLABBAJAJHCARETHEMISMEDLINCOLNVALIANTLABSIGACHIMcap ₹799 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt10.50.00.0
Net Debt-63.1-53.2-53.2
Total Debt/Equity0.030.000.00
Net Debt/Equity-0.19-0.15-0.15
Total Debt/EBITDA0.170.000.00
Net Debt/EBITDA-1.04-0.86-0.82
Interest Coverage (EBIT/Interest)84.24106.58106.58
Total Debt/Total Capital %3.120.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.